These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. New antifungal agents in pediatric practice. Das S; Shivaprakash MR; Chakrabarti A Indian Pediatr; 2009 Mar; 46(3):225-31. PubMed ID: 19346570 [TBL] [Abstract][Full Text] [Related]
7. Management of invasive fungal infections: a role for polyenes. Chandrasekar P J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children]. Jullien V Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286 [TBL] [Abstract][Full Text] [Related]
9. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. Metcalf SC; Dockrell DH J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in antifungal chemotherapy. Petrikkos G; Skiada A Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic implications for use of antifungal agents. Lewis RE Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Smith J; Andes D Ther Drug Monit; 2008 Apr; 30(2):167-72. PubMed ID: 18367976 [TBL] [Abstract][Full Text] [Related]
13. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. Rogers TR; Frost S Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371 [TBL] [Abstract][Full Text] [Related]
14. Voriconazole concentrations and outcome of invasive fungal infections. Miyakis S; van Hal SJ; Ray J; Marriott D Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698 [TBL] [Abstract][Full Text] [Related]
15. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Worth LJ; Blyth CC; Booth DL; Kong DC; Marriott D; Cassumbhoy M; Ray J; Slavin MA; Wilkes JR Intern Med J; 2008 Jun; 38(6b):521-37. PubMed ID: 18588523 [TBL] [Abstract][Full Text] [Related]
16. Azole antifungals: 35 years of invasive fungal infection management. Allen D; Wilson D; Drew R; Perfect J Expert Rev Anti Infect Ther; 2015 Jun; 13(6):787-98. PubMed ID: 25843556 [TBL] [Abstract][Full Text] [Related]
18. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
19. Antifungal treatment in pediatric patients. Zaoutis TE; Benjamin DK; Steinbach WJ Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Stockmann C; Constance JE; Roberts JK; Olson J; Doby EH; Ampofo K; Stiers J; Spigarelli MG; Sherwin CM Clin Pharmacokinet; 2014 May; 53(5):429-54. PubMed ID: 24595533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]